Document And Entity Information
Document And Entity Information - shares | 3 Months Ended | |
Mar. 31, 2024 | May 01, 2024 | |
Document Information [Line Items] | ||
Entity Central Index Key | 0001659617 | |
Entity Registrant Name | Moleculin Biotech, Inc. | |
Amendment Flag | false | |
Current Fiscal Year End Date | --12-31 | |
Document Fiscal Period Focus | Q1 | |
Document Fiscal Year Focus | 2024 | |
Document Type | 10-Q | |
Document Quarterly Report | true | |
Document Period End Date | Mar. 31, 2024 | |
Document Transition Report | false | |
Entity File Number | 001-37758 | |
Entity Incorporation, State or Country Code | DE | |
Entity Tax Identification Number | 47-4671997 | |
Entity Address, Address Line One | 5300 Memorial Drive, Suite 950 | |
Entity Address, City or Town | Houston | |
Entity Address, State or Province | TX | |
Entity Address, Postal Zip Code | 77007 | |
City Area Code | 713 | |
Local Phone Number | 300-5160 | |
Entity Current Reporting Status | Yes | |
Entity Interactive Data Current | Yes | |
Entity Small Business | true | |
Entity Filer Category | Non-accelerated Filer | |
Entity Emerging Growth Company | false | |
Entity Shell Company | false | |
Title of 12(b) Security | Common Stock, par value $0.001 per share | |
Trading Symbol | MBRX | |
Security Exchange Name | NASDAQ | |
Entity Common Stock, Shares Outstanding | 2,311,536 |
Condensed Consolidated Balance
Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($) $ in Thousands | Mar. 31, 2024 | Dec. 31, 2023 |
Current assets: | ||
Cash and cash equivalents | $ 16,824 | $ 23,550 |
Prepaid expenses and other current assets | 2,133 | 2,723 |
Total current assets | 18,957 | 26,273 |
Furniture and equipment, net | 240 | 272 |
Intangible assets | 11,148 | 11,148 |
Operating lease right-of-use asset | 500 | 524 |
Total assets | 30,845 | 38,217 |
Liabilities, Current [Abstract] | ||
Accounts payable | 2,104 | 2,498 |
Accrued expenses and other current liabilities | 3,304 | 4,317 |
Total current liabilities | 5,408 | 6,815 |
Operating lease liability - long-term, net of current portion | 450 | 474 |
Warrant liability - long-term | 3,400 | 4,855 |
Total liabilities | 9,258 | 12,144 |
Commitments and contingencies (Note 7) | ||
Stockholders' equity | ||
Preferred stock, $0.001 par value; 5,000,000 shares authorized, no shares issued or outstanding | 0 | 0 |
Common stock, $0.001 par value; 100,000,000 shares authorized; 2,311,536 and 2,227,516 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively | 2 | 33 |
Additional paid-in capital | 158,177 | 157,653 |
Accumulated other comprehensive income (loss) | (18) | (9) |
Accumulated deficit | (136,574) | (131,604) |
Total stockholders’ equity | 21,587 | 26,073 |
Total liabilities and stockholders’ equity | $ 30,845 | $ 38,217 |
Condensed Consolidated Balanc_2
Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - $ / shares | Mar. 31, 2024 | Dec. 31, 2023 |
Preferred stock, par value (in dollars per share) | $ 0.001 | $ 0.001 |
Preferred stock, shares authorized (in shares) | 5,000,000 | 5,000,000 |
Preferred stock, shares issued (in shares) | 0 | 0 |
Preferred stock, shares outstanding (in shares) | 0 | 0 |
Common stock, par or stated value per share (in dollars per share) | $ 0.001 | $ 0.001 |
Common stock, shares authorized (in shares) | 100,000,000 | 100,000,000 |
Common stock, shares issued (in shares) | 2,311,536 | 2,227,516 |
Common stock, shares outstanding (in shares) | 2,311,536 | 2,227,516 |
Condensed Consolidated Statemen
Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) $ in Thousands | 3 Months Ended | |
Mar. 31, 2024 | Mar. 31, 2023 | |
Revenues | $ 0 | $ 0 |
Operating expenses: | ||
Research and development | 4,252 | 5,687 |
General and administrative | 2,393 | 2,637 |
Depreciation and amortization | 32 | 30 |
Total operating expenses | 6,677 | 8,354 |
Loss from operations | (6,677) | (8,354) |
Other income: | ||
Gain from change in fair value of warrant liability | 1,455 | 39 |
Other income, net | 11 | 8 |
Interest income, net | 241 | 392 |
Net loss | $ (4,970) | $ (7,915) |
Net loss per common share - basic and diluted (in dollars per share) | $ (2.02) | $ (4.13) |
Weighted average common shares outstanding, basic and diluted (in shares) | 2,466,174 | 1,916,665 |
Net loss | $ (4,970) | $ (7,915) |
Other comprehensive loss: | ||
Foreign currency translation | (9) | (4) |
Comprehensive loss | $ (4,979) | $ (7,919) |
Condensed Consolidated Statem_2
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands | 3 Months Ended | |
Mar. 31, 2024 | Mar. 31, 2023 | |
Cash flows from operating activities: | ||
Net loss | $ (4,970) | $ (7,915) |
Adjustments to reconcile net loss to net cash used in operating activities: | ||
Depreciation and amortization | 32 | 30 |
Stock-based compensation | 493 | 499 |
License rights expense settled in stock | 0 | 772 |
Change in fair value of warrant liability | (1,455) | (39) |
Operating lease, net | 108 | 110 |
Changes in operating assets and liabilities: | ||
Prepaid expenses and other current assets | 590 | 427 |
Accounts payable | (394) | (156) |
Accrued expenses and other current liabilities | (1,121) | 255 |
Net cash used in operating activities | (6,717) | (6,017) |
Cash flows from financing activities: | ||
Proceeds from sale of common stock, net of issuance costs | 0 | 141 |
Net cash provided by financing activities | 0 | 141 |
Effect of exchange rate changes on cash and cash equivalents | (9) | (4) |
Net decrease in cash and cash equivalents | (6,726) | (5,880) |
Cash and cash equivalents, - beginning of period | 23,550 | 43,145 |
Cash and cash equivalents, - end of period | $ 16,824 | $ 37,265 |
Condensed Consolidated Statem_3
Condensed Consolidated Statements of Stockholders' Equity (Unaudited) - USD ($) $ in Thousands | Common Stock [Member] | Additional Paid-in Capital [Member] | Retained Earnings [Member] | AOCI Attributable to Parent [Member] | Total |
Balance (in shares) at Dec. 31, 2022 | 1,908,522 | ||||
Balance at Dec. 31, 2022 | $ 29 | $ 153,985 | $ (101,835) | $ 12 | $ 52,191 |
Issuance of common stock in connection with Consulting Agreements (in shares) | 10,026 | ||||
Issuance of common stock in connection with Consulting Agreements | $ 0 | 141 | 0 | 0 | 141 |
Stock-based compensation | 0 | 499 | 0 | 0 | 499 |
Net loss | 0 | 0 | (7,915) | 0 | (7,915) |
Cumulative translation adjustment | $ 0 | 0 | 0 | (4) | (4) |
Common stock issued for license rights (in shares) | 54,808 | ||||
Common stock issued for license rights | $ 1 | 771 | 0 | 0 | 772 |
Balance (in shares) at Mar. 31, 2023 | 1,973,356 | ||||
Balance at Mar. 31, 2023 | $ 30 | 155,396 | (109,750) | 8 | 45,684 |
Balance (in shares) at Dec. 31, 2023 | 2,227,516 | ||||
Balance at Dec. 31, 2023 | $ 33 | 157,653 | (131,604) | (9) | 26,073 |
Issuance of common stock in connection with Consulting Agreements (in shares) | 6,834 | ||||
Issuance of common stock in connection with Consulting Agreements | $ 0 | 37 | 0 | 0 | 37 |
Reverse stock split (in shares) | 77,186 | ||||
Reverse stock split | $ (31) | 31 | 0 | 0 | 0 |
Stock-based compensation | 0 | 456 | 0 | 0 | 456 |
Net loss | 0 | 0 | (4,970) | 0 | (4,970) |
Cumulative translation adjustment | $ 0 | 0 | 0 | (9) | (9) |
Balance (in shares) at Mar. 31, 2024 | 2,311,536 | ||||
Balance at Mar. 31, 2024 | $ 2 | $ 158,177 | $ (136,574) | $ (18) | $ 21,587 |
Note 1 - Nature of Business
Note 1 - Nature of Business | 3 Months Ended |
Mar. 31, 2024 | |
Notes to Financial Statements | |
Nature of Operations [Text Block] | 1. The terms “MBI” or “the Company”, “we”, “our” and “us” are used herein to refer to Moleculin Biotech, Inc. MBI is a clinical-stage pharmaceutical company, organized as a Delaware corporation in July 2015, three one 1 two not not third not In 2019, On May 5, 2023, 30 5550 2 not 5810 3 180 November 1, 2023, November 2, 2023, April 29, 2024, March 5, 2024, 1 11:59 March 21, 2024, March 22, 2024. April 8, 2024, 5550 2 10 March 22, 2024 April 5, 2024. |
Note 2 - Basis of Presentation,
Note 2 - Basis of Presentation, Principles of Consolidation, and Significant Accounting Policies | 3 Months Ended |
Mar. 31, 2024 | |
Notes to Financial Statements | |
Significant Accounting Policies [Text Block] | 2. Reverse Stock Split - March 22, 2024, 1 Basis of Presentation – Condensed Consolidated Financial Information - 10 8 X. not not December 31, 2023 10 March 22, 2024. Principles of Consolidation one Significant Accounting Policies 2, Basis of Presentation, principles of consolidation and significant accounting policies 10 December 31, 2023 no three March 31, 2024 Use of Estimates - may may may Going Concern and Liquidity March 31, 2024 t of million since inception and had not million a March 31, 2024 not one not one third no In March 2022, none 19. not not may the three March 31, 2024 2023 , the Company expensed approximately $0.1 million and $0.5 milli The Company is in the process of filing a claim with its insurance carriers related to this loss which may not not . Accordingly, the Company has not not not Cash and Cash Equivalents one may not not Fair Value of Financial Instruments - The Company has categorized its assets and liabilities that are valued at fair value on a recurring basis into a three 1 3 Assets and liabilities recorded in the balance sheets at fair value are categorized based on a hierarchy of inputs as follows: Level 1 Level 2 Level 3 The Company’s financial assets and liabilities recorded at fair value on a recurring basis include the fair value of warrant liability discussed in Note 4. The following table provides the financial liabilities reported at fair value and measured on a recurring basis at March 31, 2024 December 31, 2023 Description Fair Value Level 1 Level 2 Level 3 Fair value of warrant liability as of March 31, 2024: $ 3,400 $ — $ — $ 3,400 Fair value of warrant liability as of December 31, 2023: $ 4,855 $ — $ — $ 4,855 The table below of Level 3 first first 3 may not not Three Months Ended March 31, 2024 Warrant Liability Long-Term Balance, December 31, 2023 $ 4,855 Change in fair value - net (1,455 ) Balance, March 31, 2024 $ 3,400 Loss Per Common Share three March 31, 2024 2023 y 1.7 million and 0.4 million, respectively, of potentially dilutive shares were excluded from the computation of diluted earnings per share due to their anti-dilutive effect. Subsequent Events - 8 Recent Accounting Pronouncements no |
Note 3 - Accrued Expenses and O
Note 3 - Accrued Expenses and Other Current Liabilities | 3 Months Ended |
Mar. 31, 2024 | |
Notes to Financial Statements | |
Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block] | 3. Accrued expenses and other current liabilities consist of the following components (in thousands): March 31, 2024 December 31, 2023 Accrued research and development $ 1,565 $ 2,845 Accrued payroll and bonuses 1,092 765 Accrued legal, regulatory, professional and other 477 547 Operating lease liability - current 109 100 Accrued liabilities due to related party 61 60 Total accrued expenses $ 3,304 $ 4,317 Additionally, accounts payable inclu des $74,000 a March 31, 2024 December 31, 2023 |
Note 4 - Warrants
Note 4 - Warrants | 3 Months Ended |
Mar. 31, 2024 | |
Notes to Financial Statements | |
Warrants Disclosure [Text Block] | 4. Liability Classified Warrants The Company uses the Black-Scholes option pricing model (BSM) to determine the fair value of its warrants at the date of issue and outstanding at each reporting date. The risk-free interest rate assumption is based upon observed interest rates on zero The assumptions used in determining the fair value of the Company's outstanding liability classified warrants are as follows: March 31, 2024 December 31, 2023 Risk-free interest rate 4.2% to 5.5% 3.8% to 5.4% Volatility 88.1% to 108.7% 79.5% to 108.7% Expected life (years) 0.1 to 4.7 0.3 to 5.0 Dividend yield —% —% A summary of the Company's liability classified warrant activity during the three March 31, 2024 Number of Shares Range of Warrant Exercise Weighted Average Weighted Average Remaining Contractual Under Warrant Price per Share Exercise Price Life (Years) Balance at January 1, 2024 1,082,895 $ 9.60 $ 157.50 $ 24.32 5.1 Expired warrants (17,573 ) $ 99.00 $ 99.00 $ 99.00 — Balance at March 31, 2024 1,065,322 $ 9.60 $ 157.50 $ 23.09 4.4 Exercisable at March 31, 2024 1,065,322 $ 9.60 $ 157.50 $ 23.09 4.4 For a summary of the changes in fair value associated with the Company's warrant liability for the three March 31, 2024 2 Equity Classified Warrants In March 2024, ten four At March 31, 2024 had 292,611 eq d 266,591 w December 31, 2023 The Company recorded stock compensation expense for the non-employee consulting agreements o f $34,000 a three March 31, 2024 2023 March 31, 2024 |
Note 5 - Equity
Note 5 - Equity | 3 Months Ended |
Mar. 31, 2024 | |
Notes to Financial Statements | |
Equity [Text Block] | 5. Lincoln Park Equity Line The Company did not 2021 three March 31, 2024 2021 as $19.8 mi March 31, 2024 July 1, 2024. no December 2023 not June 26, 2024. Other Components of Equity In March 2024, Stock-Based Compensation and Outstanding Awards The 2015 May 2023 2022, 2015 may March 31, 2024 e 2,053 shar 2015 Stock-based compensation expense for the three March 31, 2024 2023 Three Months Ended March 31, 2024 2023 General and administrative $ 381 $ 369 Research and development 112 130 Total stock-based compensation expense $ 493 $ 499 On May 8, 2024 2015 two |
Note 6 - Income Taxes
Note 6 - Income Taxes | 3 Months Ended |
Mar. 31, 2024 | |
Notes to Financial Statements | |
Income Tax Disclosure [Text Block] | 6. Deferred income tax assets and liabilities are determined based upon differences between the financial reporting and tax basis of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The Company does not 2024 three March 31, 2024 2024 not” not March 31, 2024 December 31, 2023 The Company recorded no income tax provision for the three March 31, 2024 2023 three March 31, 2024 2023 nil. 162 no |
Note 7 - Commitments and Contin
Note 7 - Commitments and Contingencies | 3 Months Ended |
Mar. 31, 2024 | |
Notes to Financial Statements | |
Commitments and Contingencies Disclosure [Text Block] | 7. In addition to the commitments and contingencies described elsewhere in these notes, see below for a discussion of the Company's commitments and contingencies as of March 31, 2024 Lease Obligations Payable The following summarizes quantitative information about the Company's operating leases for the three March 31, 2024 2023 Three Months Ended March 31, 2024 2023 Lease cost: Operating lease cost $ 38 $ 33 Variable lease cost 2 7 Total $ 40 $ 40 I n September 2023, August 31, 2029, pproximately $4,700 which will increase at an average approximate rate of 2% In June 2022, September 30, 2027, no i three March 31, 2024 2023 as and $38,000 for the three March 31, 2024 2023 , respectively Licenses MD Anderson - ere and $64,000 for the three March 31, 2024 2023 , respectively HPI - two f for e three March 31, 2024 2023 Sponsored Research Agreements - were and $155,000 for the three March 31, 2024 2023 , respectively . |
Note 8 - Subsequent Events
Note 8 - Subsequent Events | 3 Months Ended |
Mar. 31, 2024 | |
Notes to Financial Statements | |
Subsequent Events [Text Block] | 8. In addition to the subsequent events discussed elsewhere in these notes, no March 31, 2024 |
Insider Trading Arrangements
Insider Trading Arrangements | 3 Months Ended |
Mar. 31, 2024 | |
Insider Trading Arr Line Items | |
Material Terms of Trading Arrangement [Text Block] | 5. During the period covered by this Quarterly Report, none 10b5 1 10b5 1 408 1934, |
Rule 10b5-1 Arrangement Adopted [Flag] | false |
Non-Rule 10b5-1 Arrangement Adopted [Flag] | false |
Rule 10b5-1 Arrangement Terminated [Flag] | false |
Non-Rule 10b5-1 Arrangement Terminated [Flag] | false |
Significant Accounting Policies
Significant Accounting Policies (Policies) | 3 Months Ended |
Mar. 31, 2024 | |
Accounting Policies [Abstract] | |
Reverse Stock Split [Policy Text Block] | Reverse Stock Split - March 22, 2024, 1 |
Basis of Accounting, Policy [Policy Text Block] | Basis of Presentation – Condensed Consolidated Financial Information - 10 8 X. not not December 31, 2023 10 March 22, 2024. |
Consolidation, Policy [Policy Text Block] | Principles of Consolidation one |
Significant Accounting Policies [Policy Text Block] | Significant Accounting Policies 2, Basis of Presentation, principles of consolidation and significant accounting policies 10 December 31, 2023 no three March 31, 2024 |
Use of Estimates, Policy [Policy Text Block] | Use of Estimates - may may may |
Going Concern Policy [Policy Text Block] | Going Concern and Liquidity March 31, 2024 t of million since inception and had not million a March 31, 2024 not one not one third no In March 2022, none 19. not not may the three March 31, 2024 2023 , the Company expensed approximately $0.1 million and $0.5 milli The Company is in the process of filing a claim with its insurance carriers related to this loss which may not not . Accordingly, the Company has not not not |
Cash and Cash Equivalents, Policy [Policy Text Block] | Cash and Cash Equivalents one may not not |
Fair Value of Financial Instruments, Policy [Policy Text Block] | Fair Value of Financial Instruments - The Company has categorized its assets and liabilities that are valued at fair value on a recurring basis into a three 1 3 Assets and liabilities recorded in the balance sheets at fair value are categorized based on a hierarchy of inputs as follows: Level 1 Level 2 Level 3 The Company’s financial assets and liabilities recorded at fair value on a recurring basis include the fair value of warrant liability discussed in Note 4. The following table provides the financial liabilities reported at fair value and measured on a recurring basis at March 31, 2024 December 31, 2023 Description Fair Value Level 1 Level 2 Level 3 Fair value of warrant liability as of March 31, 2024: $ 3,400 $ — $ — $ 3,400 Fair value of warrant liability as of December 31, 2023: $ 4,855 $ — $ — $ 4,855 The table below of Level 3 first first 3 may not not Three Months Ended March 31, 2024 Warrant Liability Long-Term Balance, December 31, 2023 $ 4,855 Change in fair value - net (1,455 ) Balance, March 31, 2024 $ 3,400 |
Earnings Per Share, Policy [Policy Text Block] | Loss Per Common Share three March 31, 2024 2023 y 1.7 million and 0.4 million, respectively, of potentially dilutive shares were excluded from the computation of diluted earnings per share due to their anti-dilutive effect. |
Subsequent Events, Policy [Policy Text Block] | Subsequent Events - 8 |
New Accounting Pronouncements, Policy [Policy Text Block] | Recent Accounting Pronouncements no |
Note 2 - Basis of Presentatio_2
Note 2 - Basis of Presentation, Principles of Consolidation, and Significant Accounting Policies (Tables) | 3 Months Ended |
Mar. 31, 2024 | |
Notes Tables | |
Fair Value Measurements, Recurring and Nonrecurring [Table Text Block] | Description Fair Value Level 1 Level 2 Level 3 Fair value of warrant liability as of March 31, 2024: $ 3,400 $ — $ — $ 3,400 Fair value of warrant liability as of December 31, 2023: $ 4,855 $ — $ — $ 4,855 Three Months Ended March 31, 2024 Warrant Liability Long-Term Balance, December 31, 2023 $ 4,855 Change in fair value - net (1,455 ) Balance, March 31, 2024 $ 3,400 |
Note 3 - Accrued Expenses and_2
Note 3 - Accrued Expenses and Other Current Liabilities (Tables) | 3 Months Ended |
Mar. 31, 2024 | |
Notes Tables | |
Schedule of Accrued Liabilities [Table Text Block] | March 31, 2024 December 31, 2023 Accrued research and development $ 1,565 $ 2,845 Accrued payroll and bonuses 1,092 765 Accrued legal, regulatory, professional and other 477 547 Operating lease liability - current 109 100 Accrued liabilities due to related party 61 60 Total accrued expenses $ 3,304 $ 4,317 |
Note 4 - Warrants (Tables)
Note 4 - Warrants (Tables) | 3 Months Ended |
Mar. 31, 2024 | |
Notes Tables | |
Schedule of Warrants or Rights, Assumptions Used [Table Text Block] | March 31, 2024 December 31, 2023 Risk-free interest rate 4.2% to 5.5% 3.8% to 5.4% Volatility 88.1% to 108.7% 79.5% to 108.7% Expected life (years) 0.1 to 4.7 0.3 to 5.0 Dividend yield —% —% |
Schedule of Warrant Activity [Table Text Block] | Number of Shares Range of Warrant Exercise Weighted Average Weighted Average Remaining Contractual Under Warrant Price per Share Exercise Price Life (Years) Balance at January 1, 2024 1,082,895 $ 9.60 $ 157.50 $ 24.32 5.1 Expired warrants (17,573 ) $ 99.00 $ 99.00 $ 99.00 — Balance at March 31, 2024 1,065,322 $ 9.60 $ 157.50 $ 23.09 4.4 Exercisable at March 31, 2024 1,065,322 $ 9.60 $ 157.50 $ 23.09 4.4 |
Note 5 - Equity (Tables)
Note 5 - Equity (Tables) | 3 Months Ended |
Mar. 31, 2024 | |
Notes Tables | |
Share-based Payment Arrangement, Expensed, Amount [Table Text Block] | Three Months Ended March 31, 2024 2023 General and administrative $ 381 $ 369 Research and development 112 130 Total stock-based compensation expense $ 493 $ 499 |
Note 7 - Commitments and Cont_2
Note 7 - Commitments and Contingencies (Tables) | 3 Months Ended |
Mar. 31, 2024 | |
Notes Tables | |
Lease, Cost [Table Text Block] | Three Months Ended March 31, 2024 2023 Lease cost: Operating lease cost $ 38 $ 33 Variable lease cost 2 7 Total $ 40 $ 40 |
Note 1 - Nature of Business (De
Note 1 - Nature of Business (Details Textual) | 6 Months Ended | ||||
Mar. 22, 2024 | Mar. 21, 2024 | Apr. 29, 2024 | Mar. 31, 2024 | May 05, 2023 $ / shares | |
Number of Core Drug Technologies | 3 | ||||
NASDAQ Compliance, Minimum Closing Bid Price Per Share (in dollars per share) | $ 1 | ||||
NASDAQ Compliance, Extension Period (Day) | 180 days | ||||
Reverse Stock Split [Member] | |||||
Stockholders' Equity Note, Stock Split, Conversion Ratio | 15 | 15 | |||
Animal Life Sciences, Inc [Member] | |||||
Equity Method Investment, Ownership Percentage | 10% |
Note 2 - Basis of Presentatio_3
Note 2 - Basis of Presentation, Principles of Consolidation, and Significant Accounting Policies (Details Textual) $ in Thousands, shares in Millions | 3 Months Ended | 12 Months Ended | ||||
Mar. 22, 2024 | Mar. 21, 2024 | Mar. 31, 2024 USD ($) shares | Mar. 31, 2023 USD ($) shares | Dec. 31, 2022 | Dec. 31, 2023 USD ($) | |
Number of Operating Segments | 1 | |||||
Retained Earnings (Accumulated Deficit) | $ (136,574) | $ (131,604) | ||||
Cash | $ 16,800 | |||||
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares) | shares | 1.7 | 0.4 | ||||
General and Administrative Expense [Member] | ||||||
Legal Fees | $ 100 | $ 500 | ||||
Reverse Stock Split [Member] | ||||||
Stockholders' Equity Note, Stock Split, Conversion Ratio | 15 | 15 |
Note 2 - Basis of Presentatio_4
Note 2 - Basis of Presentation, Principles of Consolidation and Significant Accounting Policies - Schedule of Fair Value Measurements, Recurring and Nonrecurring (Details) - USD ($) $ in Thousands | 3 Months Ended | |
Mar. 31, 2024 | Dec. 31, 2023 | |
Warrant Liability Long Term [Member] | ||
Balance | $ 4,855 | |
Change in fair value - net | (1,455) | |
Balance | 3,400 | |
Fair Value, Recurring [Member] | Warrant Liability [Member] | ||
Fair value of warrant liability | 3,400 | $ 4,855 |
Fair Value, Recurring [Member] | Warrant Liability [Member] | Fair Value, Inputs, Level 1 [Member] | ||
Fair value of warrant liability | 0 | 0 |
Fair Value, Recurring [Member] | Warrant Liability [Member] | Fair Value, Inputs, Level 2 [Member] | ||
Fair value of warrant liability | 0 | 0 |
Fair Value, Recurring [Member] | Warrant Liability [Member] | Fair Value, Inputs, Level 3 [Member] | ||
Fair value of warrant liability | $ 3,400 | $ 4,855 |
Note 3 - Accrued Expenses and_3
Note 3 - Accrued Expenses and Other Current Liabilities (Details Textual) - USD ($) | Mar. 31, 2024 | Dec. 31, 2023 |
Accounts Payable, Current | $ 2,104,000 | $ 2,498,000 |
Related Party [Member] | ||
Accounts Payable, Current | $ 74,000 | $ 67,000 |
Note 3 - Accrued Expenses and_4
Note 3 - Accrued Expenses and Other Current Liabilities - Accrued Expenses and Other Current Liabilities (Details) - USD ($) $ in Thousands | Mar. 31, 2024 | Dec. 31, 2023 |
Accrued research and development | $ 1,565 | $ 2,845 |
Accrued payroll and bonuses | 1,092 | 765 |
Accrued legal, regulatory, professional and other | 477 | 547 |
Operating lease liability - current | 109 | 100 |
Accrued Liabilities, Current | 3,304 | 4,317 |
Related Party [Member] | ||
Accrued Liabilities, Current | $ 61 | $ 60 |
Note 3 - Accrued Expenses and_5
Note 3 - Accrued Expenses and Other Current Liabilities - Accrued Expenses and Other Current Liabilities (Details) (Parentheticals) - USD ($) $ in Thousands | Mar. 31, 2024 | Dec. 31, 2023 |
Liabilities, Current [Abstract] | ||
Accrued Liabilities, Current | $ 3,304 | $ 4,317 |
Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration] | Accrued Liabilities, Current |
Note 4 - Warrants (Details Text
Note 4 - Warrants (Details Textual) - USD ($) | 3 Months Ended | ||
Mar. 31, 2024 | Mar. 31, 2023 | Dec. 31, 2023 | |
Share-Based Payment Arrangement, Expense | $ 493,000 | $ 499,000 | |
Equity Classified Warrants [Member] | |||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | 3,334 | ||
Warrants and Rights Outstanding, Term (Year) | 10 years | ||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ 9.15 | ||
Class of Warrant or Right, Outstanding (in shares) | 292,611 | 289,276 | |
Class of Warrant or Right, Vested and Exercisable (in shares) | 266,591 | 266,350 | |
Share-Based Payment Arrangement, Expense | $ 34,000 | $ 46,000 | |
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount | $ 344,000 |
Note 4 - Warrants - Assumptions
Note 4 - Warrants - Assumptions Used (Details) | Mar. 31, 2024 | Dec. 31, 2023 |
Minimum [Member] | Measurement Input, Risk Free Interest Rate [Member] | ||
Warrants, assumptions | 0.042 | 0.038 |
Minimum [Member] | Measurement Input, Price Volatility [Member] | ||
Warrants, assumptions | 0.881 | 0.795 |
Minimum [Member] | Measurement Input, Expected Term [Member] | ||
Warrants, assumptions | 0.1 | 0.3 |
Maximum [Member] | Measurement Input, Risk Free Interest Rate [Member] | ||
Warrants, assumptions | 0.055 | 0.054 |
Maximum [Member] | Measurement Input, Price Volatility [Member] | ||
Warrants, assumptions | 1.087 | 1.087 |
Maximum [Member] | Measurement Input, Expected Term [Member] | ||
Warrants, assumptions | 4.7 | 5 |
Note 4 - Warrants - Warrant Act
Note 4 - Warrants - Warrant Activity (Details) - Liability Classified Warrants [Member] - $ / shares | 3 Months Ended | 12 Months Ended |
Mar. 31, 2024 | Dec. 31, 2023 | |
Balance (in shares) | 1,082,895 | |
Balance, weighted average remaining contractual life (Year) | 4 years 4 months 24 days | 5 years 1 month 6 days |
Expired warrants (in shares) | (17,573) | |
Balance (in shares) | 1,065,322 | 1,082,895 |
Exercisable (in shares) | 1,065,322 | |
Exercisable, weighted average remaining contractual life (Year) | 4 years 4 months 24 days | |
Minimum [Member] | ||
Balance, warrant exercise price (in dollars per share) | $ 9.6 | |
Expired warrants (in dollars per share) | 99 | |
Balance, warrant exercise price (in dollars per share) | 9.6 | $ 9.6 |
Exercisable, warrant exercise price (in dollars per share) | 9.6 | |
Maximum [Member] | ||
Balance, warrant exercise price (in dollars per share) | 157.5 | |
Expired warrants (in dollars per share) | 99 | |
Balance, warrant exercise price (in dollars per share) | 157.5 | 157.5 |
Exercisable, warrant exercise price (in dollars per share) | 157.5 | |
Weighted Average [Member] | ||
Balance, warrant exercise price (in dollars per share) | 24.32 | |
Expired warrants (in dollars per share) | 99 | |
Balance, warrant exercise price (in dollars per share) | 23.09 | $ 24.32 |
Exercisable, warrant exercise price (in dollars per share) | $ 23.09 |
Note 5 - Equity (Details Textua
Note 5 - Equity (Details Textual) - USD ($) $ in Millions | 3 Months Ended | ||||
May 08, 2024 | May 31, 2023 | May 31, 2022 | Mar. 31, 2024 | Dec. 31, 2023 | |
Stock Issued During Period, Shares, Issued for Services (in shares) | 6,834 | ||||
The 2015 Stock Plan [Member] | |||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized (in shares) | 116,667 | 133,334 | |||
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized (in shares) | 366,667 | ||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant (in shares) | 2,053 | ||||
The 2015 Stock Plan [Member] | Subsequent Event [Member] | |||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures (in shares) | 1,000 | ||||
Lincoln Park Transaction [Member] | |||||
Purchase Agreement, Common Stock, Available Amount | $ 19.8 |
Note 5 - Equity - Stock based C
Note 5 - Equity - Stock based Compensation (Details) - USD ($) $ in Thousands | 3 Months Ended | |
Mar. 31, 2024 | Mar. 31, 2023 | |
Share-Based Payment Arrangement, Expense | $ 493 | $ 499 |
General and Administrative Expense [Member] | ||
Share-Based Payment Arrangement, Expense | 381 | 369 |
Research and Development Expense [Member] | ||
Share-Based Payment Arrangement, Expense | $ 112 | $ 130 |
Note 6 - Income Taxes (Details
Note 6 - Income Taxes (Details Textual) - USD ($) Pure in Thousands, $ in Thousands | 3 Months Ended | |
Mar. 31, 2024 | Mar. 31, 2023 | |
Income Tax Expense (Benefit) | $ 0 | $ 0 |
Effective Income Tax Rate Reconciliation, Percent | 0% | 0% |
Note 7 - Commitments and Cont_3
Note 7 - Commitments and Contingencies (Details Textual) - USD ($) | 1 Months Ended | 3 Months Ended | |
Sep. 30, 2023 | Mar. 31, 2024 | Mar. 31, 2023 | |
Operating Lease, Monthly Rent Payment | $ 4,700 | ||
Operating Lease, Rent Expense, Annual Increase In Rent, Percent | 2% | ||
Sublease Income | $ 12,000 | $ 12,000 | |
Operating Lease, Payments | 29,000 | 38,000 | |
License Agreements Expense | 156,000 | 155,000 | |
Houston Pharmaceuticals, Inc [Member] | |||
Related Party Transaction, Amounts of Transaction | 59,000 | 59,000 | |
MD Anderson [Member] | |||
License Agreements Expense | $ 54,000 | $ 64,000 |
Note 7 - Commitments and Cont_4
Note 7 - Commitments and Contingencies - Lease Cost (Details) - USD ($) $ in Thousands | 3 Months Ended | |
Mar. 31, 2024 | Mar. 31, 2023 | |
Operating lease cost | $ 38 | $ 33 |
Variable lease cost | 2 | 7 |
Total | $ 40 | $ 40 |